Cargando…
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)
Afatinib is an ErbB family blocker approved for the treatment of epidermal growth factor receptor mutation‐positive nonsmall‐cell lung cancer. A pivotal trial demonstrated significant clinical benefits with manageable toxicity of afatinib as a second‐line treatment option in squamous cell carcinoma...
Autores principales: | Lee, Seung Hyeun, Park, Cheol‐Kyu, Lee, Sung Yong, Choi, Chang‐Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046099/ https://www.ncbi.nlm.nih.gov/pubmed/33586312 http://dx.doi.org/10.1111/1759-7714.13880 |
Ejemplares similares
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018) -
Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020) -
New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021) -
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
por: Machiels, Jean-Pascal H, et al.
Publicado: (2014) -
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable,
EGFR
mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
por: Choi, Juwhan, et al.
Publicado: (2022)